Facebook Twitter Email
DECEMBER 12, 2000

The Food and Drug Administration is seeking to disqualify a University of Pennsylvania gene therapy researcher whose work resulted in the death of a student in 1999.

The FDA's disqualification would prevent James Wilson from testing experimental drugs or other products on human subjects. Wilson has until December 30 to respond in writing to a letter the FDA sent him for violating government clinical study regulations. The FDA also sent warning letters to two of Wilson's associates.

The family of Jesse Gelsinger filed a wrongful death suit against the university in September.

Get the Story:
FDA Seeks to Penalize Gene Scientist (The Washington Post 12/12)

Related Stories:
Clinical Trials, Human Subject Protection, the FDA - www.fda.gov/oc/oha/default.htm

Related Stories:
Experts issue gene research warning (The Medicine Wheel 09/19)
Doctor foresees benefits for Indians (The Medicine Wheel 09/19)
Tribes wanted for health program (The Medicine Wheel 9/18)
Scientists decode human genome (Tech 06/27)